Clinical trials: Hepatic Tumor Resection
Colorectal Neoplasms, Liver Neoplasms
Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone.
- Trial name
- NCT00143403
- Testing
- Irinotecan + 5 FU + folinic acid, Folinic Acid + 5 FU
- Where
- 66 sites in Belgium, Denmark and 14 more
- Volunteers
- 321 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
The purpose of this study is to see if Panitumumab plus the other treatments will increase the time of remission. Remission means that there is no sign of the cancer.
- Trial name
- NCT01312857
- Testing
- panitumumab, Randomization to No Panitumumab
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Malignant Neoplasm
Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection
The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection.
- Trial name
- NCT03575806
- Testing
- TACE plus autologous Tcm immunotherapy, TACE
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences